| Document |
Document Title |
|
WO/2022/122773A1 |
The present invention relates to 4-(2-Fluoro-4-methoxy-5-3-(((l- methylcyclobutyl)methyl)carbamoyl)bicyclo[2.2.1]heptan-2-yl)
carbamoyl)phenoxy)-l-methylcyclohexane-l-carboxylic acid derivatives and similar compounds of formula (I) as R...
|
|
WO/2022/125636A1 |
Methods are provided for modulating MRGPRX2 generally, or for treating a MRGPRX2 dependent condition more specifically, by contacting the MRGPRX2 or administering to a subject in need thereof, respectively, an effective amount of a compo...
|
|
WO/2022/056346A9 |
Oral dosage forms comprising eltrombopag choline, processes for preparation thereof and methods of use thereof are disclosed. The compositions disclosed exhibit enhanced bioavailability and reduced food effect compared to commercially av...
|
|
WO/2022/118959A1 |
The problem addressed by the present invention is to provide a compound used in the formation of an optically anisotropic film that excels in a reverse wavelength dispersion property and a heat-and-moisture durability property, a polymer...
|
|
WO/2022/118951A1 |
The present invention addresses the problem of providing: a compound to be used in forming an optically anisotropic film having excellent reverse wavelength dispersion properties; a polymerizable composition; an optically anisotropic fil...
|
|
WO/2022/111493A1 |
A use of a complex of an ARB metabolite and an NEP inhibitor in the preparation of drugs for the prevention and/or treatment of nephropathy.
|
|
WO/2022/111605A1 |
The present disclosure relates to an aryl or heteroaryl substituted 5-membered aromatic heterocyclic compound and the use thereof. In particular, provided is a compound as shown in formula I or a pharmaceutically acceptable salt thereof,...
|
|
WO/2022/111694A1 |
The present invention relates to a quinazolinone compound, a preparation method therefor and an application thereof. The compound has a structure represented by formula (I) or formula (LI), has an excellent HPPD inhibitory effect and a s...
|
|
WO/2022/108261A1 |
The present invention provides a heterocyclic compound represented by chemical formula 1, an organic light-emitting device comprising same, and a composition for forming an organic layer.
|
|
WO/2022/106596A1 |
The invention relates to a composition comprising (i) a specific pyrazole or an agriculturally acceptable salt thereof; (ii) a phosphonic acid or an agriculturally acceptable salt thereof; (iii) optionally, one or more carboxylic acids, ...
|
|
WO/2022/100614A1 |
Disclosed are a benzourea ring derivative as represented by formula (I) or a pharmaceutically acceptable salt thereof, and a preparation method therefor and the use thereof.
|
|
WO/2022/099374A1 |
The present invention relates to a compound of formula (I): or a salt or solvate thereof, combinations comprising same, uses and methods thereof, and kits comprising same.
|
|
WO/2022/100625A1 |
The present invention relates to novel compounds effectively antagonizing LPAR, which are a compound as shown in formula (I), or a stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug of the compound as shown in fo...
|
|
WO/2022/096679A1 |
The present invention relates to compounds that modulate the conformation of Aurora Kinase A (AURKA). The compounds of the present invention are also modulators of the interactome of AURKA, and preferably alter the protein-protein intera...
|
|
WO/2022/096450A1 |
The present invention relates to the use of [(1,5-diphenyl-1H-pyrazol-3-yl)oxy] acetic acid derivatives of the formula (I) and their salts (I) and compositions containing them, for reducing phytotoxic effects of agrochemicals, in particu...
|
|
WO/2022/094244A1 |
Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (I SR) and for treating related diseases, disorders, and conditions.
|
|
WO/2022/090071A1 |
The present invention relates to the use of mefenpyr-diethyl for controlling phytopathogenic fungi. Further the invention relates to methods for controlling phytopathogenic fungi, wherein the fungi, their habitat, their locus, or the pla...
|
|
WO/2022/090069A1 |
The present invention relates to compositions comprising mefenpyr-diethyl and a compound selected from mefentrifluconazole, metyltetraprole, benzovindiflupyr, pydiflumetofen, inpyrflux-am, isoflucypram, cyclobutrifluram, fluindapyr, pyra...
|
|
WO/2022/089604A1 |
Provided are crystalline forms of a KRAS G12C inhibitor compound and to processes for their preparation. Furthermore, provided is pharmaceutical composition comprising said crystalline forms, and at least one pharmaceutically acceptable ...
|
|
WO/2022/092310A1 |
The present invention provides a compound, etc. which has aldehyde dehydrogenase 2 (ALDH2) activating activity. Provided are a compound represented by formula (1), a pharmaceutically acceptable salt thereof, and a prodrug thereof. [In th...
|
|
WO/2022/083703A1 |
This disclosure relates to LPA antagonists of Formula (I) : including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.
|
|
WO/2022/081552A1 |
Described herein are compounds that are kinase inhibitors. The disclosed compounds have improved properties that lead to specific targeting of kinases without inhibiting the activity of related enzymes including, making them useful for t...
|
|
WO/2022/080812A1 |
The present invention relates to a novel method for producing an intermediate expressed by chemical formula 6 that can be effectively used in synthesis of sphingosine-1-phosphate receptor agonist.
|
|
WO/2022/076628A1 |
This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having the structure: (I), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis usin...
|
|
WO/2022/076741A1 |
Compounds derived from celecoxib and valdecoxib, and methods of use thereof, are disclosed. The compounds are useful for, inter alia, identifying and localizing the site of pathology and/or inflammation responsible for the sensation of p...
|
|
WO/2022/068848A1 |
Disclosed herein is 3- [ (1H-pyrazol-4-yl) oxy] pyrazin-2-amine compounds of Formula (I), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions comprising thereof. Also disclosed is a m...
|
|
WO/2022/068816A1 |
Provided are a dendrene amide compound, a bactericide and the use thereof, which relate to the field of pesticides. The compound has a structure as shown in formula (I). The dendrene amide compound provided has a relatively high inhibito...
|
|
WO/2022/070069A1 |
Disclosed are compounds, compositions and methods for treating diseases, disorders, or medical conditions that are affected by the modulation of DHODH. Such compounds are represented by Formula (I) as follows, wherein R1, R2, R3, and R4 ...
|
|
WO/2022/071896A1 |
The invention discloses novel pharmaceutically acceptable salts of eltrombopag and process for preparing the same. The invention also relates to solid state forms of eltrombopag sesquiethanolamine and processes for the preparation thereo...
|
|
WO/2022/063134A1 |
Provided is the use of a CSF1R kinase inhibitor compound or a pharmaceutically acceptable salt thereof in the preparation of drugs for treating diseases related to the CSF1R kinase signal transduction pathway or drugs for regulating immu...
|
|
WO/2022/064453A1 |
The present invention relates to novel N-linker heterocyclic fluoroalkenyl compounds of formula (I), Formula (I) wherein, R1, R2, R3, ring A and Y are as defined in the detailed description. The present invention further relates to their...
|
|
WO/2022/063050A1 |
The present invention relates to a pyrazole compound and a preparation method therefor and a use thereof. In particular, the present invention relates to a compound shown in formula I, a pharmaceutical composition containing same or a ph...
|
|
WO/2022/067165A1 |
The present disclosure describes in one aspect tetrahydropyridine compounds of formula (I), which are 5-HT2A receptor agonists that exhibit selective binding to the 5-HT2A receptor over the 5-HT2B receptor. In certain embodiments, the co...
|
|
WO/2022/067114A1 |
The present disclosure relates to compounds, pharmaceutical compositions comprising such compounds, and use of such compounds in methods of treatment or in medicaments for treatment of inflammatory diseases and certain neurological disor...
|
|
WO/2022/058733A1 |
The present invention relates to compounds for stabilising the native tetrameric form of transthyretin and protecting it from proteolytic cleavage; compounds for use in the prevention and treatment of transthyretin amyloidosis; and agent...
|
|
WO/2022/061008A2 |
Methods are provided for modulating MRGPR X4 generally, or for treating a MRGPR X4-dependent condition more specifically, by contacting MRGPR X4 or administering to a subject in need thereof, respectively, an effective amount of a compou...
|
|
WO/2022/053659A2 |
The use of a heterocyclic compound of the general formula (I) with the following definitions: X S or NR4 with R4 being C1-4-alkyl, R1 C3-12-hydrocarbon residue which can contain 1 to 3 heteroatoms selected from the group consisting of ni...
|
|
WO/2022/053000A1 |
Provided are a compound of general formula (I) or a stereoisomer, deuterium, solvate, prodrug, metabolite, and pharmaceutically acceptable salt or co-crystal thereof, an intermediate thereof, and a preparation method therefor, and an app...
|
|
WO/2022/056100A1 |
The present invention provides processes and key intermediates for the synthesis of (S)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl
)-1-(1,1,1-trifluoropropane-2-yl)-1H-pyrazole-4-carboxamide.
|
|
WO/2022/049376A1 |
The invention relates to compounds of formula (I): and related aspects.
|
|
WO/2022/051384A1 |
This disclosure provides novel compounds and methods for inhibiting BAX activity and BAX-mediated apoptosis, as well as compounds and methods for treating or preventing BAX- mediated disorders.
|
|
WO/2022/049272A1 |
The invention provides novel heterocyclic compounds having the general formula (I), and pharmaceutically acceptable salts thereof, wherein R1 to R9 and p are as described herein. (I) Further provided are pharmaceutical compositions inclu...
|
|
WO/2022/049377A1 |
The invention relates to compounds of formula (I) and related aspects.
|
|
WO/2022/047014A1 |
The present disclosure relates to copper complexes, pharmaceutical compositions comprising these complexes, chemical processes for preparing these complexes, and their use in the treatment of neurodegenerative disease, e.g., amyotrophic ...
|
|
WO/2022/043374A1 |
The present invention relates to compounds of formula (II) wherein R1-R5, X and L are as described herein, and pharmaceutically acceptable salts thereof, compositions including the compounds and methods of using the compounds, particular...
|
|
WO/2022/043877A1 |
: The present invention relates to the processes for the preparation of substituted pyrazole derivatives of formula (I), (II), (III), (IV), (IV-a) (V), (VII), which are useful as intermediates in anthranilamide insecticides production. I...
|
|
WO/2022/043503A1 |
The present invention relates to c-di-GMP lowering chemical compounds having anti- biofilm properties. In particular, the present invention relates to anti-biofilm compounds or salts or tautomers thereof for use in treatment and/or preve...
|
|
WO/2022/040005A1 |
Disclosed are anti-angiogenic agents that target Pfn1:actin interaction. Also disclosed are compounds for treating ocular diseases or conditions. Further disclosed are compounds for treating cancer.
|
|
WO/2022/037601A1 |
A compound capable of effectively antagonizing an EP4 receptor, which compound is a compound as represented by formula (I), and a tautomer, a stereoisomer, a hydrate, a solvate, a pharmaceutically acceptable salt or a prodrug thereof, wh...
|
|
WO/2022/036455A1 |
Herein is described a pharmaceutical composition for agonizing CB2 receptor activity, medical kits, therapeutic applications thereof, and methods of making and using such compositions. The composition comprises a combination of: - a firs...
|
